Sensorion: €88M in Cash and Short-Term Deposits, SENS-601 Enters Clinical Phase
Sensorion published its first-half 2026 financial statements on September 23, 2026, marked by cash and short-term deposits of €88 million and the refocusing of its resources on SENS-601, its gene therapy program against deafness linked to GJB2 gene mutations. The Montpellier biotech company obtained authorization from the ANSM in August 2026 to launch the HearConnex Phase I/II trial in France, while recording an increase in its half-year net loss.
Net Loss Increased to €20.7 Million in First Half 2026
In the first half of 2026, Sensorion recorded a net loss of €20.7 million, compared to €16.0 million a year earlier. Research and development expenses increased by 9%, rising from €15.0 million to €16.4 million, an increase the company attributed to higher expenses related to gene therapies. General and administrative expenses amounted to €7.7 million, compared to €4.1 million in the first half of 2025, an increase the company linked primarily to changes in the management team during the period. Operating loss came in at €21.4 million, compared to €16.8 million a year earlier.
€88 Million in Cash and Short-Term Deposits to Finance Activities Through End of 2027
As of June 30, 2026, cash, cash equivalents, and short-term deposits classified as current assets amounted to €88 million, compared to €47.5 million on December 31, 2025. The company estimates that this position enables it to finance its activities through the end of 2027. In April 2026, Sensorion concluded a support agreement with Bpifrance for the GJB2-GT program, under the France 2030 investment plan (ConnexGene project). This financing, provided as a repayable advance, covers the period from January 1, 2026 to January 1, 2030, for a total amount that could reach €10.3 million subject to applicable conditions. An initial advance of €2.6 million was received in May 2026.
SENS-601 Targeting First Patient Treated in Early 2027
Sensorion has concentrated its resources on SENS-601, its single-vector AAV gene therapy aimed at restoring hearing in patients with deafness linked to the GJB2 gene. Following the submission of clinical trial applications in France and Canada, with Fast Track procedure granted in France, the company received authorization from the ANSM in August 2026 to launch the HearConnex Phase I/II trial. The company aims to administer treatment to the first patient in HearConnex in early 2027. It also plans to submit an IND application in the United States and a clinical trial application in Australia by the end of 2026. In parallel, Sensorion decided in June 2026 to discontinue clinical development of SENS-501, its gene therapy program for otoferlin-related deafness, in order to concentrate its resources on SENS-601. The company also informed its social and economic committee of a reorganization project, for which consultation is underway and the financial impact of which has not yet been estimated.
